<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154501</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-6016o-HV-101</org_study_id>
    <nct_id>NCT04154501</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects</brief_title>
  <official_title>A Study to Evaluate the Safety and Pharmacokinetics of Single Doses of CNTX-6016 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrexion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrexion Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an
      open-label, 2-period crossover, food effect cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Actual">August 26, 2019</completion_date>
  <primary_completion_date type="Actual">August 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of single doses of CNTX-6016 - TEAEs</measure>
    <time_frame>Up to 80 days</time_frame>
    <description>Information regarding treatment emergent adverse events was collected during each dose cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Proportionality of a single doses of CNTX-6016 in healthy subjects</measure>
    <time_frame>40 days</time_frame>
    <description>Dose Proportionality of a single doses of CNTX-6016 in healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by Tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - t1/2</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by t1/2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - AUC 0-t</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by AUC 0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - AUC 0-inf</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by AUC 0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - AUC 0-t/inf</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by AUC 0-t/inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - CL/F</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by CL/F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - Vz/F</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by Vz/F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Gender on CNTX-6016 Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 80 days</time_frame>
    <description>Effect of Gender on the systemic exposure to CNTX-6016 measured by Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Gender on CNTX-6016 Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 80 days</time_frame>
    <description>Effect of Gender on the systemic exposure to CNTX-6016 measured by tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Gender on CNTX-6016 Pharmacokinetics - t1/2</measure>
    <time_frame>Up to 80 days</time_frame>
    <description>Effect of Gender on the systemic exposure to CNTX-6016 measured by t1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Gender on CNTX-6016 Pharmacokinetics - AUC</measure>
    <time_frame>Up to 80 days</time_frame>
    <description>Effect of Gender on the systemic exposure to CNTX-6016 measured by AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Fasted or Fed State on CNTX-6016 Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 in fasted or fed state as measured by Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Fasted or Fed State on CNTX-6016 Pharmacokinetics - Tmax</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 in fasted or fed state as measured by Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Fasted or Fed State on CNTX-6016 Pharmacokinetics - t1/2</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 in fasted or fed state as measured by t1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Fasted or Fed State on CNTX-6016 Pharmacokinetics - AUC</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Systemic exposure to CNTX-6016 in fasted or fed state as measured by AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion</measure>
    <time_frame>Up to 6 days</time_frame>
    <description>Urine was collected over a 3-day period (0-72 hrs) in Cohort 8 and analyzed for concentrations of CNTX-6016 in subjects in both the fasted and fed states using Liquid Chromatography Mass Spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and Urine Metabolite Mining</measure>
    <time_frame>5 days</time_frame>
    <description>Urine was collected over a 3-day period (0-72hrs) in Cohort 9 (1000mg) and analyzed for concentrations of parent and metabolites of CNTX-6016 using Liquid Chromatography Mass Spectrometry.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Nociceptive Pain</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTX-6016</intervention_name>
    <description>Oral Dose CNTX-6016</description>
    <arm_group_label>Cohort 1 Drug</arm_group_label>
    <arm_group_label>Cohort 2 Drug</arm_group_label>
    <arm_group_label>Cohort 3 Drug</arm_group_label>
    <arm_group_label>Cohort 4 Drug</arm_group_label>
    <arm_group_label>Cohort 5 Drug</arm_group_label>
    <arm_group_label>Cohort 6 Drug</arm_group_label>
    <arm_group_label>Cohort 7 Drug</arm_group_label>
    <arm_group_label>Cohort 8 Fasted</arm_group_label>
    <arm_group_label>Cohort 8 Fed</arm_group_label>
    <arm_group_label>Cohort 9 Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: Placebo</intervention_name>
    <description>Oral Dose Placebo</description>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Placebo</arm_group_label>
    <arm_group_label>Cohort 5 Placebo</arm_group_label>
    <arm_group_label>Cohort 6 Placebo</arm_group_label>
    <arm_group_label>Cohort 7 Placebo</arm_group_label>
    <arm_group_label>Cohort 9 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Is in good general health as determined by Investigator's review.

          -  Has a body mass index (BMI) between 18 and 35 kg/m2.

          -  Non- or ex-smoker (&gt; 1 year) and has not used any nicotine containing products within
             12 months prior to screening.

          -  For females, is not currently pregnant and is either of non-childbearing potential or
             willing to use an adequate method of birth control.

          -  For males, must agree to use barrier contraception and not to donate sperm.

        Key Exclusion Criteria:

          -  History of or active cardiac disease, including congestive heart failure, angina, or
             any arrhythmia.

          -  Has any history or currently active type of cancer except excised or cured basal cell
             carcinoma.

          -  Has a gastrointestinal disorder that could interfere with the absorption of orally
             administered drugs.

          -  Has asthma or other severe respiratory disease (e.g., chronic obstructive pulmonary
             disease) requiring daily prescription medicine.

          -  Currently has kidney, neurologic, metabolic, or liver disease, or other organ system
             disease.

          -  Has a history, current evidence, or is being treated for depression, suicidal
             ideation, suicide attempt, or any other current psychiatric condition requiring active
             treatment.

          -  Has an immunological disorder such as, but not limited to, human immunodeficiency
             virus (HIV), acquired, or congenital immune deficiency syndrome; autoimmune diseases,
             such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus,
             seronegative spondyloarthropathies or vasculitis, or any infection.

          -  Has positive screening test for hepatitis B virus (HBV) or hepatitis C virus (HCV).

          -  Is pregnant, lactating, or planning a pregnancy during the study.

          -  Has used any prescribed medication within 30 days prior to the first admission or has
             plans to use any prescribed medication during the study (with the exception of
             hormonal contraceptives).

          -  Positive urine screen for alcohol, cotinine, THC and/or drugs of abuse.

          -  Ingestion of food or beverages containing grapefruit and/or grapefruit juice and/or
             pomelos during the 7 days prior to dosing and/or during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall M Stevens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centrexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Pain</keyword>
  <keyword>Nociceptive Pain</keyword>
  <keyword>Mixed Pain</keyword>
  <keyword>Cannabinoid</keyword>
  <keyword>Cannabinoid-2 Receptor Agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

